ArticleCNS neuroscience & therapeutics2017
Fibroblast growth factor 22 is a novel modulator of depression through interleukin-1β.
Article in CNS neuroscience & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- FGF13 alleviates astrocytic apoptosis via JIP2 inhibition in the hippocampus and mitigates depression-like behavior.Journal of neuroinflammation · 2026Article
- FGF family in health and disease.Molecular biomedicine · 2026Review
- FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems.Journal of advanced research · 2025Review
- The Promising Role of Selected Fibroblast Growth Factors as Potential Markers of Complications in Type 1 and Type 2 Diabetes.International journal of molecular sciences · 2025Article
- Pathology and Therapeutic Significance of Fibroblast Growth Factors.Targets (Basel) · 2025Article
- Behavioral Animal Models and Neural-Circuit Framework of Depressive Disorder.Neuroscience bulletin · 2025Review
- Fibroblast Growth Factors: Roles and Emerging Therapeutic Applications.Current drug targets · 2025Review
- Biocompatible Macroion/Growth Factor Assemblies for Medical Applications.Biomolecules · 2023Review
- Stress, hypoglycemia, and the autonomic nervous system.Autonomic neuroscience : basic & clinical · 2022Review
- New developments in the biology of fibroblast growth factors.WIREs mechanisms of disease · 2022Review
- Selection of the Male or Female Sex in Chronic Unpredictable Mild Stress-Induced Animal Models of Depression.BioMed research international · 2022Review
- Animal models for the study of depressive disorder.CNS neuroscience & therapeutics · 2021Review
- Roles of Fibroblast Growth Factors and Their Therapeutic Potential in Treatment of Ischemic Stroke.Frontiers in pharmacology · 2021Review
- Optimization of food deprivation and sucrose preference test in SD rat model undergoing chronic unpredictable mild stress.Animal models and experimental medicine · 2020Article
- Fibroblast Growth Factors in Depression.Frontiers in pharmacology · 2019Review
- Fibroblast growth factor 22 is a novel modulator of depression through interleukin-1β.CNS neuroscience & therapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsEmerging evidence shows that fibroblast growth factor 22 (FGF22) plays a critical role in the etiology of depression. However, the molecular mechanisms of FGF22 are not fully comprehended. Here, the effect of FGF22 in depression and its relationship with interleukin-1β (IL-1β) were investigated in clinical, animal, and cell experiments.
methodsSerum from depressive patients was collected, and the levels of FGF22 and IL-1β were analyzed by ELISA. The chronic unpredictable mild stress (CUMS) model was established, and primary hippocampal neuronal cells were cultured to examine changes in FGF22 and IL-1β levels in rat hippocampus.
resultsThe results revealed a negative correlation between serum FGF22 levels and serum IL-1β levels. The expression of IL-1β in the CUMS rat hippocampus decreased, and the apoptosis of hippocampal cells improved after the injection of lentiviral vector-mediated FGF22 (LV-FGF22). Further tests in primary hippocampal neuronal cells also showed a reduction in IL-1β and the cell apoptosis rate after treatment with FGF22.
conclusionIn conclusion, the results revealed that FGF22 plays a role in alleviating depression, which may be mediated by reduced expression of IL-1β.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.